Biogen (BIIB) Stock Forecast & Price Target

$211.17

-16.27 (-7.15%)

(As of 07/26/2024 ET)

Biogen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 26 Analyst Ratings

Based on 26 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 9 have given a hold rating, and 17 have given a buy rating for BIIB.

Consensus Price Target

$286.00
35.44% Upside

High Forecast	$373.00
Average Forecast	$286.00
Low Forecast	$200.00

According to the 26 analysts' twelve-month price targets for Biogen, the average price target is $286.00. The highest price target for BIIB is $373.00, while the lowest price target for BIIB is $200.00. The average price target represents a forecasted upside of 35.44% from the current price of $211.17.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	18 Buy rating(s)	21 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$286.00	$286.50	$293.88	$331.19
Forecasted Upside	35.44% Upside	27.73% Upside	29.32% Upside	19.34% Upside

Get Biogen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto Swap Profits

625,000% Gain

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.65	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	35.44% Upside	3,121.53% Upside	9.09% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/26/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$294.00 ➝ $294.00	+38.96%
7/12/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$335.00 ➝ $313.00	+32.18%
7/3/2024	William Blair 2 of 5 stars		Reiterated Rating	Outperform
6/26/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$317.00 ➝ $317.00	+41.11%
5/23/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+33.21%
5/16/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$340.00 ➝ $340.00	+48.35%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
5/3/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$339.00 ➝ $342.00	+57.23%
4/29/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$270.00 ➝ $270.00	+24.58%
4/25/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$215.00 ➝ $200.00	-1.27%
4/25/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$213.00 ➝ $215.00	+6.44%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$250.00 ➝ $214.00	+11.37%
4/12/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$280.00 ➝ $260.00	+27.65%
4/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$270.00 ➝ $240.00	+19.08%
2/22/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$355.00 ➝ $277.00	+25.31%
2/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$311.00	+43.02%
2/20/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$310.00 ➝ $305.00	+39.35%
2/14/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$333.00 ➝ $316.00	+42.91%
2/14/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$295.00 ➝ $285.00	+28.15%
2/14/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$315.00 ➝ $240.00	+5.89%
2/12/2024	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$290.00 ➝ $280.00	+14.82%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
12/14/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$315.00 ➝ $287.00	+12.30%
12/7/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$283.00	+21.01%
11/10/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$361.00 ➝ $373.00	+65.93%
8/8/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$282.00 ➝ $275.00	+1.39%
7/27/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform	$327.00	+23.28%
5/11/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$320.00 ➝ $350.00	+11.73%
5/1/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$270.00 ➝ $350.00	+15.04%
2/16/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$300.00 ➝ $315.00	+12.91%
12/1/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$370.00	+22.16%
11/30/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$325.00 ➝ $350.00	+20.11%
10/26/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$270.00 ➝ $300.00	+6.36%
10/26/2022	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$270.00 ➝ $310.00	+13.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:24 AM ET.

BIIB Forecast - Frequently Asked Questions

What is Biogen's forecast for 2024?: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $286.00, with a high forecast of $373.00 and a low forecast of $200.00.
Should I buy or sell Biogen stock right now?: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIIB shares.
Does Biogen's stock price have much upside?: According to analysts, Biogen's stock has a predicted upside of 27.45% based on their 12-month stock forecasts.
What analysts cover Biogen?: Biogen has been rated by research analysts at HC Wainwright, HSBC, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, Truist Financial, and William Blair in the past 90 days.
Do Wall Street analysts like Biogen more than its competitors?: Analysts like Biogen less than other "medical" companies. The consensus rating score for Biogen is 2.65 while the average consensus rating score for "medical" companies is 2.72. Learn more on how BIIB compares to other companies.